Ferring Says Supply of DDAVP Injectable to Return in “One to Two Months”
Montreal, June 23, 2021 – Ferring Canada, in discussions with the Canadian Hemophilia Society, has stated that supply of DDAVP, the 15 mcg/mL formulation of desmopressin, injected subcutaneously, for the treatment of mild hemophilia A, Type 1 von Willebrand disease and platelet disorders, will resume in “one or two months.” The shortage was apparently caused by shipping issues. Ferring had earlier cited a global manufacturing issue to explain the stoppage in supply to Canadian pharmacies.
The worldwide production of Octostim Spray, inhaled through the nose, remains stopped and is not expected to resume until 2023.
Patients who use either of the formulations should contact their treatment centre for advice on alternatives.
For more information, please visit the Canadian Hemophilia Society.
Hemophilia Ontario’s Member Support and Services is always here to help answer any questions you may have. Feel free to contact Bojan Pirnat at bpirnat@hemophilia.on.ca or 647-354-5660.
